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ABSTRACT  
Background: Contemplating the severity of pandemic sequel for public health many researchers are working recklessly for new targeted drug s 
and vaccines. Despite the challenging opportunities, the setup for the development of new effective remedy against COVID-19 is unforeseeable.  
Objective: The aim of the present review was to explore the work done by some authors to battle against COVID-19.  
Material & Method: We analysed 24 articles from Elsevier and one from J Med virology journals stating different strategies to cope with this 
recently arrived monster COVID-19. Further are some targeting therapies viz., Niclosamide, immune response generated by cytotoxic T-cells 
and Natural Killer cells, Chloroquine and Hydroxy Chloroquine, blockade of Interleukin17, N- Acetylcysteine, mucolytic agents, oxytocin, 
bioflavonoids, triterpenoid saponins, ACE inhibitors or AII receptor antagonists, Hyperbaric oxygen therapy, serum albumin, R itonavir, 
Tocilizumab, Furin, Amantadine, pioglitazone, Dapsone and doxycycline, steroids, plasama therapy, routine childhood immunization, a data-
driven hypothesis on the epigenetic dysregulation of host metabolism by SARS corona viral infection, lipid metabolism has bee n proposed as a 
treatment target for COVID-19, COVIDiagnosis-Net proposed network for quick and accurate diagnosis.  
Result: We got to know how the people are struggling to find a cure for this pandemic affair. 
Conclusion: Till date, there is no specific treatment that has been confirmed to the effect against COVID-19. Let’s hope for the best. 
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The outbreak of novel coronavirus disease 2019 (COVID-19) 
which was originated in Wuhan, Hubei, China, in December 
2019, has been declared as public health emergency of 
international concern by World Health Organization (WHO). 
On 30 January 2020, the WHO Director-General declared 
that the current outbreak constituted a public health 
emergency of international concern, and on 12 March 2020 
the COVID-19 outbreak was declared a pandemic [1].  In the 
face of rapidly spreading disease and a large number of 
infected people, there is an urgent need for effective COVID-
19 prevention and control measures. WHO has declare that 
there are currently no known treatment for COVID-19 and 
does not recommend the use of antiviral drugs, antibiotics, 
glucocorticoids, or traditional Chinese medicine. Even that, 
there have been reports of the use of many antibiotics and 
steroids viz., oseltamivir, lopinavir /ritonavir, prednisone, 
antibiotics, and traditional Chinese medicine for the 
treatment of patients with COVID-19 [2]. 
Contemplating the severity of pandemic sequel for public 
health many researchers are working recklessly for new 
targeted drugs and vaccines. Despite the challenging 
opportunities, the setup for the development of new 
effective remedy against COVID-19 is unforeseeable.  
In this present review we focused on different emerging 
strategies to gear up with SARS-CoV-2. Here are some 
proposed hypotheses for the treatment of COVID-19 by 
some authors from reputed journals using diverse types of 
targeted therapies to brawl against it. 
SOME PROPOSED HYPOTHESES:  
Drug repurposing is an attractive approach for bringing new 
drugs quickly into market. Various drug repurposing screens 
identified NIC as a potential drug candidate against COVID-
19. Prevention of viral entry by altering endosomal pH and 
prevention of viral replication by inhibition of autophagy are 
the plausible mechanisms of NIC against COVID-19.  SARS-
CoV-2 infects the permissive cells through the receptor of 
angiotensin converting enzyme -2 (ACE-2).  Spike (S) 
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protein, 3C-like main protease, NTPase / helicase, RNA 
dependent RNA polymerase (RNA replicase) and host 
receptors are the crucial drug targets of SARS-CoV-2. NIC 
was reported to pH dependent endocytosis of human rhino 
virus (HRV) and influenza. This mechanism may also 
contribute to the antiviral effects of NIC against SAR-CoV-2. 
Moreover, NIC can prevent autophagy of SARS-CoV-2 by 
inhibition of S-Phase kinase associated protein 2 (SKP2). 
Clinical efficacy of NIC against COVID-19, therefore, need to 
be evaluated against COVID-19.  
S.K.S.S. Pindiprolu and S.H. Pindiprolu hypothesized, the 
potential antiviral mechanisms of (Niclosamide) NIC against 
COVID-19.  They utilized an attractive approach that is, 
“Drug repurposing, by employing ‘old’ drugs to treat ‘new’ 
diseases in drug discovery” by using Niclosamide (NIC) 
which is an approved anti-helminthic drug with diverse 
antiviral mechanisms [3]. 
A. Yaqinuddin and J. Kashir suggested that the Cytotoxic T-
cells (CTLs) and Natural Killer (NK) cells are essential to 
generate an effective immune response against resultant 
disease (COVID-19) which is more severe in individuals with 
a weak immune system and patients with severe COVID-19 
which present significantly lower lymphocyte, and higher 
neutrophil, counts in blood specifically, CD8+ lymphocytes 
and NK cells compared to patients with mild infection and 
healthy individuals. COVID-19 severity could be treated via 
Interferon therapy to generate adequate immune response, 
use of chloroquine, broad-based antibiotics and antivirals to 
limit viral replication and co-infections and use of 
Monalizumab to restore the function of CD8+ T and NK cells. 
It is observed that the patients with COVID-19 showed 
significantly lower lymphocyte and higher neutrophil counts 
in blood compared to healthy controls. The NK group 2 
member A (NKG2A) heterodimeric receptor is one of the 
most prominent NK cell inhibitory receptors [4].  
Over-expression of NKG2A (an inhibitory receptor) on CD8+ 
and NK cells of COVID-19 infected patients compared to 
healthy controls has been demonstrated recently. 
Suppression of the innate immune response occurs via over-
expression of NKG2A (an inhibitory receptor) on CD8+ and 
NK cells, leading to their reduction and an increase in 
opportunistic and coinfections of the lung in COVID-19 
patients with severe symptoms [4]. 
Chloroquine (CQ) and Hydroxy Chloroquine (HCQ) with 
immunomodulatory and anti-inflammatory effects, enter the 
cytoplasmic vesicles through the cytoplasmic membrane, 
and increase the pH from 4.0 to 6.0, and due to reduced pH 
acid-dependent sub cellular functions get inhibited, antigen 
processing in macrophages will be impaired and receptor 
binding and membrane fusion will also get inhibited.  
Moreover, the replication of the virus will block due to the 
change in pH required for lysosome and enzyme activities. 
Due to the mechanisms of action of these drugs, over 
activation of the immune system triggered by SARS-CoV-2 
may be suppressed and the progression to severe disease 
will be controlled [5]. 
It is observed that IL-17 increased in intensive-care COVID-
19 patients vs non intensive-care and controls hypothesizing 
that blocking IL-17 could have the potential to improve 
COVID-19s aberrant immune response and acute respiratory 
distress syndrome-related mortality. A cytokine that may be 
related to IL-6 in the condition of viral infection is IL-17. Hou 
et al. found in murine viral models that the superfluous IL-6 
level promotes the generation of Th17 cells, and the 
resulting IL-6 and IL-17 synergistically promote viral 
obstinacy by shielding virus infected cells from apoptosis. IL- 
17 blocking role in COVID19 subjects with cytokine storm 
risk as the COVID-19 patients showed lower leukocyte 
numbers, abnormal respiratory findings, and increased 
levels of plasma pro-inflammatory cytokines such as 
interleukin (IL)1-β, IL1RA, IL6, IL8, IL10 with Th1-Th17 cells 
appearing as the main source which appears as a potential 
promising therapeutic target [6]. 
5-alpha-reductase inhibitors may disrupt androgens 
metabolism in lungs, which in turn may control COVID-19 
infection. Finasteride and dutasteride both of these 
members of 5-alpha-reductase inhibitors are used to reduce 
prostate volume in Benign Prostatic Hyperplasia by blocking 
5-alpha-reductase isoform 3, which is expressed in 
respiratory epithelium and fibroblasts.  It is achieved that 
androgens including DHT disrupt broadcasting between 
fibroblasts and alveolar type II cells by a mechanism 
involving TGFβ (Transforming Growth Factor beta) and EGF 
(Epidermal Growth Factor) receptor signaling pathways. 5-
alphareductase inhibitors might enhance androgen 
concentration in lungs impeding their regeneration.  
Interstitial pneumonia is the main cause of life-threatening 
respiratory disorders at the severe stage of COVID-19 
infection [7]. 
N-Acetylcysteine (NAC), a well-known mucolytic agent used 
in respiratory infections, is a thiol-containing free-radical 
scavenger and a precursor of glutathione. The beneficial 
action of 1200 mg/d of oral NAC in respiratory diseases has 
been previously demonstrated in prevention of chronic 
obstructive pulmonary disease exacerbations and addition 
of this dose of NAC to conventional treatment improves 
oxidative stress and inflammatory response also. In the viral 
lower respiratory tract infections associated with of IL-8, IL-
6, and TNF-α expression and release in alveolar type II cells 
infected with influenza virus A and B and respiratory 
syncytial virus is inhibited by NAC. Thus, at the dose 1200 
mg/d oral NAC used in patients with COVID- 19, as a 
measure that could potentially prevent the development of 
the cytokine storm syndrome and ARDS [8]. 
Oxytocin (OT) a nonapeptide hormone acting in the body 
and the brain, constitutes a biological target against 
coronavirus infection, especially in high-risk population, 
with underlying conditions including diabetes, high blood 
pressure, cardiovascular issues and obesity. In humans, 
activation of the OT receptor, which are expressed by 
endothelial cells in the pulmonary artery, produce a 
vasodilatory effect via stimulation of the nitric oxide (NO) 
pathway which is a key signaling molecule acting as a host 
response modulator in viral infections [9]. 
Bioflavonoids are well known for many biological and 
therapeutic effects including antioxidant and antiviral 
properties. Protease MPro and the papain-like protease are 
prime importance for processing polyproteins translated 
from the viral RNA. Recent studies showed the human 
monoclonal 47D11 antibody exerted its activity to neutralize 
SARS-CoV-2 binding a conserved epitope on the spike 
receptor binding domain. This receptor action is performed 
through a mechanism independent from the receptor 
binding inhibition and could be useful to prevent or treat 
SARS-CoV-2 infection [10]. 
Saikosaponin A, Saikosaponin B, and Saikosaponin D are 
major   triterpenoid   saponins   derived   from   Bupleurum   
falcatum   L. (Umbelliferae) with valuable pharmacological 
activities.  These active components exbibit several 
immunomodulatory, anti-inflammatory, anti-bacterial, 
antiviral, and   anti-cancer   effects.   Saikosaponin A dose-
dependently inhibits the production of several inflammatory 
mediator’s ROS, TNF-a, COX-2, iNOS, and interleukins (IL-6, 
IL-8, and IL-10) which are responsible for the cytokine 
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storm of severe COVID-19 patients. Saikosaponin D could 
exhibit an anti-proliferative effect in activated T-lymphocyte, 
in part via suppression of the nucleotide-binding 
oligomerization. Saikosaponin A inhibited influenza A virus 
and reduced lung immunopathology. Saikosaponin B 
demonstrated in-vitro antiviral activity against HCoV-229E 
by inhibiting the viral attachment to cells in a dose-
dependent manner, blocking the viral penetration into cells, 
and interfering with the early stage of viral replication, such 
as virus absorption and penetration. Saikosaponin D inhibits 
the autophagic activity of Enterovirus A71. All suggest that 
Saikosaponins might hold the promise for the treatment of 
COVID-19 [11]. 
Renin-angiotensin system is the hormone system which 
regulates blood pressure and vascular resistances, as well as 
electrolytic balance; within this important system, the 
angiotensin- converting enzyme (ACE), present on the 
surface of vascular endothelial cells, in particular those of 
the lungs, is deputed to the con- version of angiotensin I to 
angiotensin II (AII), a potent vasoconstrictive peptide. The 
surface spike proteins of the ‘severe-acute-respiratory-
syndrome-coronavirus-2′ (SARS-CoV-2), the etiological 
agent of the ongoing ‘coronavirus disease 2019’ (COVID-19), 
are able to bind the ACE2 receptors. Therefore, a hypothesis 
arises: could a chronic therapeutic assumption of ACE 
inhibitors or AII receptor antagonists have induced several 
elderly and middle-aged patients to be more vulnerable to 
the Corona virus by upregulating ACE2 receptors [12]. 
Hyperbaric oxygen therapy (HBOT) is treatment designed to 
in- crease the oxygen level in the blood. As such, HBOT may 
provide a novel means of treating/ameliorating respiratory 
conditions associated with COVID-19. Packed red blood cell 
(pRBC) transfusions are a means to enhance intravascular 
oxygen-carrying capability, and, thus, increase the 
oxygenation of tissues within the body. As such, pRBC 
transfusions may provide another novel means of 
treating/ameliorating respiratory conditions associated with 
COVID-19. The kidney produces erythropoietin (EPO) a 
circulating hormone that stimulates erythropoiesis (the 
production of RBCs) by binding and activating the EPO 
receptors (EPOR) on erythroid progenitor cells. 
Erythropoiesis-stimulating agents given by injection were 
observed to significantly increase the numbers of RBCs with 
increased tissue perfusion and oxygenation over several 
weeks. The widespread availability of ESAs provides another 
means to be able to rapidly and efficient treat COVID-19 
patients. It was suggested that that chloroquine (CQ) and 
hydroxy- chloroquine (HCQ) may have a therapeutic 
potential to raise hemoglobin levels in patients. In addition, 
a recent meta- analysis of clinical trials revealed that HCQ 
treatment among patients diagnosed with diabetes mellitus 
significantly reduced their levels of hemoglobin A1c. As a 
result, CQ and HCQ treatments may help to improve 
respiratory conditions related COVID-19 by a mechanism 
consistent with the various previously considered 
treatments [13]. 
Routine childhood immunization may protect against 
COVID-19. Most routine viral vaccines are either inactivated 
or killed vaccines stimulate T Helper 1 cells (CD4+) to 
secrete many different types of cytokines as interferon 
gamma, in- terleukin-2 (IL-2), and IL-12. IL-2 provokes the 
maturation of the killer T cell and improve the cytotoxicity of 
natural killer cells recognizing and destroying cells infected 
with viruses. Using one or combined vaccination of varicella, 
Hepatitis B, MMR, Poliomyelitis, or rotavirus to either 
protect or treat the emerging epidemic of COVID-19 [14]. 
Serum albumin is a multifunctional protein known to 
interact with a range of exogenous and endogenous 
compounds. It is predominately present in the extracellular 
space, with high concentration being reported in the skin, 
guts, muscles, fluids (cerebrospinal, pleural), and secretions 
such as sweat, tear, milk, and saliva. The well- known fact 
about albumin is that there is a complex relationship be- 
tween the inflammation and albumin level in the 
extracellular matrix under various physiological and 
pathological conditions. Use of combinatorial drugs therapy, 
in which one drug inhibits the fusion and entry of the virus 
into the cells and another drug internalizes and targets 
multiple viral components inside the cell and/or cell 
signaling to halt the viral propagation. It is highly 
recommended to use albumin as a therapeutic material, 
stabilizer, and deliverer of the drugs (such as known 
antiviral drugs and traditional molecules) that could 
effectively target the extracellular and intracellular viral 
components in the therapy of patients infected with SARS-
CoV-2 [15]. 
Ritonavir, a protease inhibitor originally designed against 
HIV, has the highest potential in inhibiting main protease. 
Ritonavir was also reported effective against SARS and 
MERS. Based on these large-scale clinical trials with 
Ritonavir, in combination with other antivirals (including 
Lopinavir, Remdesivir, Ribavirin, Hydroxychloroquine, etc.) 
and adjuvants (like Ascorbic acid, Zn2+, Melatonin, etc.) can 
be initiated for Corona virus therapy [16]. 
The anti-Flu immune responses can induce bystander 
immunity that is expected to non-specifically augment 
immunity against other viral infection such as SARS-CoV-2. 
Furthermore, influenza vaccination itself would generate 
sustained immunity that overall enhance immunity against 
SARS-CoV-2. This would explain why the rate of SARS-CoV-2 
in children is low since they catch flu more than adults do. As 
such, it is expected that their immune systems be often 
alarmed against influenza, generating bystander immunity 
that harness the immune responses against related viral 
infection. Under this setting, we hypothesize that children 
generate multifactorial immunity with the repeated 
influenza exposure that would offer bystander immune 
response in case they became infected with the new SARS-
CoV-2. It might be possible also those individuals who 
received prior Flu vaccination might show mild severity of 
COVID-19 because of Flu-induced bystander effect of the 
generated immune responses which itself might cross react 
against SARS-CoV-2 [17]. 
There is evidence that some patients with severe COVID-19 
experience a cytokine storm with production of large 
quantities of interleukins, specifically IL-1 and IL-6, and 
tocilizumab is a potent blocking agent of the IL-6 receptor. 
The evidence for tocilizumab is anecdotal, this drug does 
offer hope for managing patients with severe pulmonary 
manifestations of COVID-19. If tocilizumab does prove to be 
effective, it will come at a substantial cost, both economic, as 
it is very expensive, and therapeutic, as it can only be 
delivered by intravenous infusion. It is evidence that Vitamin 
D play a role in modulating the production of the 
interleukins, thus reducing the impact of influenza. There is 
also evidence indicating that Vitamin D supplementation can 
reduce excess IL-6 levels in diabetic mice. This evidence 
suggest That Vitamin D deficiency might play a role in the 
variation in se- verity of COVID-19, such that treatment with 
Vitamin D would offer a simpler alternative to tocilizumab 
[18]. 
In the article, “2019-nCoV-SARS-CoV-2 (COVID-19) 
infection: Cruciality of Furin and relevance with cancer, 
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Cigdem Usul Afsar”, hypothesized that It is called as “spiky 
invader” because it has a role in the attachment of the virus 
to the host cell receptor ACE2, especially the lung alveolar 
epithelial cells. It is crucial to define the protease cleavage 
specificity of viruses that impact human or animal health. 
The proprotein convertase furin is found to facilitate tumour 
formation and progression. Furin’s tissue distribution is 
ubiquitous and its expression has been confirmed in a large 
spectrum of cancers, such as lung, head and neck, colon and 
gynecologic cancers and sarcomas. Furin is thought to be a 
pro-oncogenic driver in KRAS and BRAF mutant colorectal 
cancer. Aberrant expression or activity of furin may result in 
a variety of disorders such as diabetes, cancer and 
coronaviruses exploit furin for the activation of their 
glycoproteins. Since furin is highly expressed in lungs, an 
enveloped virus that infects the respiratory tract may 
successfully exploit this convertase to activate its surface 
glycoprotein [19]. 
A model has been proposed where amantadine is able to 
inhibit E-channel conductance in reconstituted lipid bilayers. 
In a medical hypothesis of “Amantadine as a drug to mitigate 
the effects of COVID-19, Gonzalo Emiliano Aranda Abreu, et 
al.,” proposed a model where amantadine could enter the 
channel formed by the E-protein of the coronavirus, being 
able to break into the hydrogen bridges formed with water, 
in the same way as it does with the viroporin of the influenza 
virus [20]. 
“Can pioglitazone be potentially useful therapeutically in 
treating patients with covid-19? Elena Carbonib et al.,”, 
suggests that pioglitazone is able to reduce many of these 
inflammatory parameters and considering that the 
comorbidity of diabetes, hypertension and cardiovascular 
disorders are indicative of a general inflammation associated 
with metabolic syndrome and lipid profile alteration, all 
conditions that can be improved by pioglitazone, we are 
therefore suggesting that a clinical trial with this drug or 
with other TZD should be considered as a support therapy in 
COVID-19. Finally, they concluded that pioglitazone can be 
administered in patients that are on statins as it has been 
reported that the addition of pioglitazone to atorvastatin, 
further reduces C-reactive protein and other laboratory 
markers of inflammation [21].  
As per the hypothesis of “Covid-19, TMPRSS2, and whether 
android regulation affects pandemic virus gender incidence 
and age distribution of disease, Steven R. Brenner”, 
hypothesized that SARS-COV2, coronavirus spike protein 
undergoes proteolytic activation by Transmembrane Serine 
Protease 2 (TMPRSS2), to enable SARS-COV-2 to utilize the 
ACE2 receptor for cellular entry. TMPRSS2 is highly 
expressed primarily in prostate epithelium, high-grade 
prostate cancers and is androgen regulated. Androgen 
regulation may explain the paucity of cases of Covid19 in 
preadolescents, since they don’t have the androgens to 
prime the TMPRSS2 cell surface protease. Covid19 has 
affected men, smokers and the elderly more than other 
groups [22]. 
In “Dapsone and doxycycline could be potential treatment 
modalities for COVID-19, Ahmed Farouka and Samar 
Salman”, suggests that dapsone and doxycycline may be 
effective in blocking inflammatory storms and, therefore, be 
a promising treatment of severe COVID-19 patients. 
Dapsone, suppresses production of specific cytokine 
signatures as IL1α, IL8, IL1β, IL6, and IL8 and tumor 
necrosis factor-α.  Also, doxycycline showed efficacy in COPD 
by inhibiting the neutrophilic inflammation and proteolytic 
activity that can be present in late COVID-19 [23].  
“Potential effect of natural and anabolizan steroids in elderly 
patient with COVID-19, Fatih Karaahmeta and Ozgur Zeliha 
Karaahmet”, suggested that endogenous pro- inflammatory 
modulation agent (estrogen and testosterone) may be 
effective in management of elderly COVID-19 by decreasing 
pro-inflammatory cytokine [24]. 
In hypothesis based on computer data, on the epigenetic 
dysregulation of host metabolism by SARS coronaviral 
infection: Potential imputations for the SARS-CoV-2 modus 
operandi presented by George D. Vavougios,  asserts that an 
exploration of SARS-CoV/human transcriptomic interaction 
data and gene set enrichment analysis (b) a confirmatory, 
focused review of the literature based on the findings by (a). 
On the experimental level, lipid metabolism on the cellular 
level has been proposed as a treatment target for COVID-19; 
specifically, both interactions between SARS CoV’s spike 
protein with lipid rich membrane compartments, as well as 
the epigenetic modulations in lipid metabolism were 
considered as the end-point targets for the development of 
small molecules, aiming to preventSARS-CoV-2infection. 
While the approach presented here is inherently limited due 
to setting its basis on the SARS-CoV proteomic interactions, 
it nevertheless presents in silico and literature evidence 
supporting SARS-CoV-2 potential to affect human 
metabolism. Furthermore, as genes affected by SARS-CoV 
infection are significantly enriched for other infections, they 
may represent a common interface, targeted by viruses [25]. 
“COVIDiagnosis-Net: Deep Bayes-SqueezeNet based 
diagnosis of the coronavirus disease 2019 (COVID-19) from 
X-ray images by Ferhat Ucara and Deniz Korkmaz”, have 
stated a model that is working with a deep learning-based 
practical structure, the early stage detections of the COVID-
19 cases could be done to manage and control the pandemic 
disease. They have demonstrated an AI-based structure to 
outperform the existing studies. The SqueezeNet that 
volunteers with its light network design is adapted for the 
COVID-19 diagnosis with Bayesian optimization additive. 
Fine-tuned hyperparameters and augmented dataset made 
the proposed network perform much better than existing 
network designs and to obtain a higher COVID-19 diagnosis 
accuracy [26]. 
Mingxiang and his team suggested that convalescent plasma 
exhibit a neutralizing antibody response directed against the 
viral S protein. This antibody blocks SARS-CoV-ACE2 entry 
and can be detected even 24 months after infection. When 
there is comparison between clinical outcomes of 
convalescent plasma therapy verses high dose steroids pulse 
therapy in SARS patients with deteriorated disease it is 
observe that patients in the plasma group had a shorter 
hospital stay and lower mortality than the comparator 
group, and no immediate adverse effect noted after plasma 
infusion. As on this discussion it is concluded that 
convalescent plasma from recovery patient would be highly 
effective weapons to win the war against COVID-19 [27]. 
There’s still a great many more to learn about SARS-CoV-2, 
the novel coronavirus originator of COVID-19. Besides it has 
been notable and satisfying to eye researchers from around 
the world to collaborate and split their valuable time, 
adroitness, and hard-merited data in the grave pursuit to 
control this death-dealing virus. 
CONCLUSION:  
Till date, there is no specific treatment that has been 
confirmed to the effect against COVID-19. In this period, 
many of the studies have published mainly on epidemiology, 
causes, clinical manifestations and diagnosis, prevention and 
control of the novel coronavirus. The above-mentioned 
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measures are an ongoing research. Studies in this domain 
are urgently needed to minimize the impact of outbreak.  
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